Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 18/20 | 0.68 |
| ▸ | CA9 | Q16790 | 17/20 | 0.68 |
| ▸ | CA12 | O43570 | 13/20 | 0.68 |
| ▸ | CA1 | P00915 | 15/20 | 0.60 |
| ▸ | MGLL | Q99685 | 1/20 | 0.59 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.47 |
| ▸ | PLG | P00747 | 1/20 | 0.46 |
| ▸ | F12 | P00748 | 1/20 | 0.46 |
| ▸ | F11 | P03951 | 1/20 | 0.46 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.46 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.46 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.46 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL585145 | 0.82 | CA2 (0.64) | CA2CA9CA12CA1MGLL | |
| SCHEMBL29955889 | 0.82 | CA2 (0.64) | CA2CA9CA12CA1MGLL | |
| SCHEMBL2846622 | 0.78 | MGLL (0.79) | CA2CA1MGLLCA14PLG | |
| SCHEMBL14653454 | 0.78 | MGLL (0.95) | CA2CA1MGLLCA14PLG | |
| SCHEMBL12619984 | 0.78 | MGLL (0.86) | CA2CA1MGLLCA14PLG | |
| SCHEMBL30712840 | 0.78 | MGLL (0.86) | CA2CA1MGLLCA14PLG | |
| SCHEMBL31139484 | 0.78 | MGLL (0.86) | CA2CA1MGLLCA14PLG | |
| SCHEMBL6168404 | 0.77 | CA2 (0.75) | CA2CA9CA12CA1CA14 | |
| SCHEMBL28129527 | 0.77 | CA2 (0.75) | CA2CA9CA12CA1CA14 | |
| SCHEMBL30786605 | 0.77 | MGLL (0.70) | CA2CA1MGLLCA14PLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9630979-B2 | Inhibitors of monoacylglycerol lipase and methods of their use | INFINITY PHARMACEUTICALS, INC. (US) | 2017-04-25 | — | — | US | disclosed |
| US-9630979-B2 | Inhibitors of monoacylglycerol lipase and methods of their use | INFINITY PHARMACEUTICALS, INC. (US) | 2017-04-25 | — | — | US | disclosed |
| US-9630979-B2 | Inhibitors of monoacylglycerol lipase and methods of their use | INFINITY PHARMACEUTICALS, INC. (US) | 2017-04-25 | — | — | US | disclosed |
| US-20140235580-A1 | INHIBITORS OF MONOACYLGLYCEROL LIPASE AND METHODS OF THEIR USE | INFINITY PHARMACEUTICALS, INC. | 2014-08-21 | — | — | US | disclosed |
| US-20140235580-A1 | INHIBITORS OF MONOACYLGLYCEROL LIPASE AND METHODS OF THEIR USE | INFINITY PHARMACEUTICALS, INC. | 2014-08-21 | — | — | US | disclosed |
| US-20140235580-A1 | INHIBITORS OF MONOACYLGLYCEROL LIPASE AND METHODS OF THEIR USE | INFINITY PHARMACEUTICALS, INC. | 2014-08-21 | — | — | US | disclosed |
| WO-2013049332-A1 | INHIBITORS OF MONOACYLGLYCEROL LIPASE AND METHODS OF THEIR USE | INFINITY PHARMACEUTICALS, INC. (US) | 2013-04-04 | — | — | WO | disclosed |
| WO-2013049332-A1 | INHIBITORS OF MONOACYLGLYCEROL LIPASE AND METHODS OF THEIR USE | INFINITY PHARMACEUTICALS, INC. (US) | 2013-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140235580-A1 | INHIBITORS OF MONOACYLGLYCEROL LIPASE AND METHODS OF THEIR USE | MGLL, PNLIP, LIPC | CA2 2949/4885CA9 2576/4885CA12 4483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.